Analyst Upgrades

• Time Warner Cable (TWC) was upgraded to outperform from market perform at Bernstein.
• Citigroup upgraded MEMC Electronic (WFR) and Skilled Healthcare (SKH) to buy from hold at Citigroup.
• Administaff (ASF) was upgraded to buy from hold at Roth Capital.
• The Buckle (BKE) was upgraded to buy from hold at KeyBanc.
• BofA/Merrill upgraded DreamWorks (DWA) to neutral from underperform.
• Corrections Corp. (CXW) was upgraded to buy from neutral at SunTrust.
• Marvell Technology (MRVL) was upgraded to positive from neutral at Susquehanna.

Analyst Upgrades

• JPMorgan upgraded Vivus (VVUS) to overweight from neutral.
• Citigroup upgraded Corn Products (CPO) to buy from hold.
• Maxim Integrated (MXIM) was upgraded to outperform from market perform at FBR Capital.
• Cardinal Health (CAH) was upgraded to outperform from neutral at RW Baird.
• Citigroup upgraded Monster Worldwide (MWW) and EchoStar (SATS) to buy from hold, as well as Las Vegas Sands (LVS) to buy from sell.
• BMO Capital upgraded Potash (POT) and Barrick Gold (ABX) to outperform from market perform.

Analyst upgrades:

• Stephens upgraded Quidel (QDEL) to equal weight from underweight on valuation following the recent pullback in shares. The firm keeps a $16 price target on the stock.
• UBS upgraded Clearwire (CLWR) to neutral from sell, citing the company's funding, which increases opportunities. The firm raised its price target to $6 from $3.
• Oppenheimer upgraded Mattson Technology (MTSN) to outperform from perform on expectations the company will benefit from a cyclical recovery in memory capex spending in 2010. The firm raised its target on shares to $4 from $3.
• Eli Lilly (LLY) was upgraded to sell from conviction sell at Goldman.
• Kinross Gold (KGC) was upgraded to overweight from neutral at JPMorgan.
• Limited Brands (LTD) was upgraded to hold from sell at Soleil.

"In all the excitement over the new future for embryonic stem cell, it seems investors have forgotten about adult stem cell products," notes growth stock specialist Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "In fact, there are adult stem cell products either already on the market or in late clinical trials. We view this as an excellent opportunity." Here, he looks at NuVasive (NASDAQ: NUVA).

"Stem cells can grow into any type of organ or tissue and the promise is that damaged organs may be repaired or even replaced with spare parts grown from stem cells. This amazing potential could revolutionize the life sciences.

"NuVasive is a rapidly growing company with unique technology for minimally-invasive back surgery; named Osteocel, it is a stem cell-based product used to help with bone grafts done as a part of spinal surgery.

Analyst upgrades:

• Royal Bank of Scotland upgraded shares of Vodafone (NYSE: VOD) to Buy from Hold to reflect the company's dividend yield.
  
• JMP Securities expects HFF Inc. (NYSE: HF) to benefit from increased U.S. commercial real estate sales and mortgage volumes. Shares were upgraded to Outperform from Market Perform. The firm has a $5 target on shares.
  
• Oppenheimer upgraded Church & Dwight (NYSE: CHD) to Outperform from Perform as it believes Church & Dwight's value-oriented portfolio should continue to benefit from the consumer trade-down and that concerns over distribution are overblown. The firm set a $62 price on shares.
• Regeneron (NASDAQ: REGN) was upgraded to Buy from Neutral at Piper Jaffray.
  
• Burlington Northern (NYSE: BNI) was raised to Buy from Neutral at Goldman.
• AMB Property (NYSE: AMB) was lifted to Neutral from Underperform at Banc of America/Merrill.

MOST NOTEWORTHY: NuVasive, Buffalo Wild Wings and Invesco were today's noteworthy initiations:

• Merriman believes NuVasive's (NASDAQ:NUVA) expanding product and distribution should continue to drive growth and feels the recent pullback provides a good entry point into shares. Merriman started NuVasive with a Buy rating.
  
• Buffalo Wild Wings (NASDAQ:BWLD) was initiated at Jefferies with a Hold rating and $30 target as they believe consensus estimates are aggressive and that shares are approaching fair valuation.
  
• William Blair believes Invesco's (NYSE:IVZ) investment capabilities and diversified client base are key differentiators that will drive superior relative growth over the long term; shares were assumed with an Outperform rating.

OTHER INITIATIONS:

• Baird initiated XenoPort (NASDAQ:XNPT) with an Outperform rating and $74 target.
  
• KeyBanc assumed Felcor Lodging (NYSE:FCH) with a Buy rating and $14 target.
  
• Trimble Navigation (NASDAQ:TRMB) was initiated at Thomas Weisel with a Market Weight rating and $30 target.

MOST NOTEWORTHY: Apple (AAPL), large-cap semis, and CDC Corp (CHINA) were today's noteworthy initiations:

• Apple (NASDAQ: AAPL) was initiated with a Buy rating and $160 target at Banc of America, as the firm still sees a significant amount of upside in the stock from Mac share gains, strong iPod unit growth, and the iPhone, which they believe is being underestimated.

• Caris believes investors should focus on companies with strong product cycles that are gaining market share. They resumed coverage of Intel (NASDAQ: INTC), Texas Instruments (NASDAQ: TXN) and National Semiconductor (NASDAQ: NSM) with Above Average ratings, and resumed Advanced Micro (NYSE: AMD) with a Sell rating; Caris started Intel with a $26 target, Texas Instruments with a $41 target, National Semi with a $29 target, and AMD with a $10 target.

• CDC Corp (NASDAQ: CHINA) was initiated at Piper Jaffray with an Outperform rating and $11.50 target.

OTHER INITIATIONS:

• Banc of America started shares of Hewlett-Packard (NYSE: HPQ), Sun Microsystems (NASDAQ: SUNW) and Dell (NASDAQ: DELL) with Buy ratings and a $56 target, $6.25 target and $35 target, and shares of IBM Corp (NYSE: IBM) with a Neutral rating and $125 target.

• BMO Capital started shares of NuVasive (NASDAQ: NUVA) with an Outperform rating and $33 target.

• Raymond James initiated shares of Petro-Canada (NYSE: PCZ) with an Outperform rating.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).